International Stem Cell Corporation
ISCO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,085 | $7,789 | $8,180 | $7,176 |
| % Growth | 16.6% | -4.8% | 14% | – |
| Cost of Goods Sold | $3,764 | $3,181 | $3,269 | $2,935 |
| Gross Profit | $5,321 | $4,608 | $4,911 | $4,241 |
| % Margin | 58.6% | 59.2% | 60% | 59.1% |
| R&D Expenses | $657 | $511 | $492 | $695 |
| G&A Expenses | $3,516 | $3,514 | $3,357 | $4,084 |
| SG&A Expenses | $4,732 | $4,760 | $4,602 | $5,467 |
| Sales & Mktg Exp. | $1,216 | $1,246 | $1,245 | $1,383 |
| Other Operating Expenses | $0 | $0 | -$13 | $13 |
| Operating Expenses | $5,389 | $5,271 | $5,094 | $6,162 |
| Operating Income | -$68 | -$663 | -$196 | -$1,921 |
| % Margin | -0.7% | -8.5% | -2.4% | -26.8% |
| Other Income/Exp. Net | -$141 | $532 | -$148 | $1,022 |
| Pre-Tax Income | -$209 | -$131 | -$331 | -$899 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$209 | -$131 | -$466 | -$1,040 |
| % Margin | -2.3% | -1.7% | -5.7% | -14.5% |
| EPS | -0.026 | -0.016 | -0.058 | -0.13 |
| % Growth | -59.1% | 71.8% | 55.2% | – |
| EPS Diluted | -0.026 | -0.016 | -0.058 | -0.13 |
| Weighted Avg Shares Out | 8,004 | 8,004 | 8,004 | 7,833 |
| Weighted Avg Shares Out Dil | 8,004 | 8,004 | 8,004 | 7,833 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $145 | $139 | $135 | $128 |
| Depreciation & Amortization | $206 | $194 | $359 | $551 |
| EBITDA | $142 | $202 | $22 | -$220 |
| % Margin | 1.6% | 2.6% | 0.3% | -3.1% |